See more : Matthews International Corporation (MATW) Income Statement Analysis – Financial Results
Complete financial analysis of ZyVersa Therapeutics, Inc. (ZVSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZyVersa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Grand Brilliance Group Holdings Limited (8372.HK) Income Statement Analysis – Financial Results
- Kontigo Care AB (publ) (KONT.ST) Income Statement Analysis – Financial Results
- Mountain Boy Minerals Ltd. (MTB.V) Income Statement Analysis – Financial Results
- Trendmaker, Inc. Limited (TMIN) Income Statement Analysis – Financial Results
- Longhui International Holdings Limited (1007.HK) Income Statement Analysis – Financial Results
ZyVersa Therapeutics, Inc. (ZVSA)
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.40K | 10.40K | 10.40K | 10.40K |
| Gross Profit | -10.40K | -10.40K | -10.40K | -10.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.21M | 5.41M | 2.12M | 6.47M |
| General & Administrative | 11.21B | 7.61M | 5.58M | 5.36M |
| Selling & Marketing | -11.20B | 0.00 | 0.00 | 0.00 |
| SG&A | 11.20M | 7.61M | 5.58M | 5.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 13.01M | 7.70M | 11.83M |
| Cost & Expenses | 14.42M | 13.01M | 7.70M | 11.83M |
| Interest Income | 0.00 | 427.54 | 821.37 | 516.45 |
| Interest Expense | -457.00K | 427.54K | 821.37K | 516.45K |
| Depreciation & Amortization | 10.40K | 10.40K | 10.40K | 10.40K |
| EBITDA | -107.74M | -11.67M | -7.25M | -12.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.42M | -13.01M | -7.70M | -11.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -93.33M | -2.37M | -379.79K | -850.11K |
| Income Before Tax | -107.75M | -14.05M | -8.08M | -12.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.46M | 745.05M | 821.37K | 516.45K |
| Net Income | -98.30M | -759.10M | -8.91M | -13.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.09K | -930.25 | -173.66 | -272.45 |
| EPS Diluted | -1.09K | -930.25 | -173.66 | -272.45 |
| Weighted Avg Shares Out | 97.50K | 25.95K | 46.55K | 46.55K |
| Weighted Avg Shares Out (Dil) | 97.50K | 25.95K | 46.55K | 46.55K |
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function, independence, personality, quality of life, and significantly increases mortality rates. Published data demonstrate that inflammasome activation increases proliferation of TNBC...
ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access
WESTON, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen...
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Noble...
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P.
WESTON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen...
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic kidney disease and its progression. WESTON, Fla.
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Thursday after the clinical-stage biopharmaceutical company priced a public share offering. ZyVersa Therapeutics is offering 4 million shares of ZVSA stock at a price of $1.25 each.
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases with high unmet needs, announced today...
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today?
ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rising higher on Wednesday after the clinical-stage specialty biopharmaceutical company highlighted the publication of a paper in a peer-reviewed journal. That paper, titled “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased...
Source: https://incomestatements.info
Category: Stock Reports
What were ZyVersa’s Q3 2024 net losses?
Net losses were approximately $2.4 million for the three months ended September 30, 2024, with an improvement of approximately $0.5 million or 17.3% compared to a net loss of approximately $2.9 million for the three months ended September 30, 2023.